
Halle C. F. Moore, MD
Advertisement
Articles by Halle C. F. Moore, MD


This video reviews a meta-analysis that looked at five studies testing the use of a gonadotropin-releasing hormone (GnRH) analog to protect ovarian function and preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.

This review will focus largely on the effects of systemic cytotoxic treatment on cognitive function, reflecting what has been most extensively studied in the literature.
Advertisement
Latest Updated Articles
An Overview of Chemotherapy-Related Cognitive Dysfunction, or ‘Chemobrain’September 15th 2014
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
4
TIP127 TroFuse-012: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab Vs Treatment of Physician’s Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
5
